Preiss, Lena C.
Lauschke, Volker M.
Georgi, Katrin
Petersson, Carl
Article History
Received: 3 November 2021
Accepted: 4 February 2022
First Online: 11 March 2022
Declarations
:
: Katrin Georgi, Lena C. Preiss, and Carl Petersson were employed by the healthcare business of Merck KGaA (Darmstadt, Germany) when this study was conducted. Volker M. Lauschke is co-founder, CEO, and shareholder of HepaPredict AB, and co-founder and shareholder PersoMedix AB. In addition, Volker M. Lauschke discloses consultancy work for EnginZyme AB. The authors have no relevant additional financial interests.